about
Systematic Review and Network Meta-Analysis of Randomized Controlled Trials: Comparative Effectiveness and Safety of Direct-Acting Antiviral Agents for Treatment-Naive Hepatitis C Genotype 1Network meta-analysis of randomized controlled trials: efficacy and safety of UDCA-based therapies in primary biliary cirrhosisSystematic review with network meta-analysis: adjuvant therapy for resected biliary tract cancerOptimal drug regimens for primary biliary cirrhosis: a systematic review and network meta-analysisSystematic review with network meta-analysis: the comparative effectiveness and safety of interventions in patients with overt hepatic encephalopathy.Establishment and Validation of SSCLIP Scoring System to Estimate Survival in Hepatocellular Carcinoma Patients Who Received Curative Liver Resection.Optimal adjuvant therapy for resected hepatocellular carcinoma: a systematic review with network meta-analysis.A network meta-analysis of the efficacy and side effects of UDCA-based therapies for primary sclerosing cholangitis.Systematic review with network meta-analysis: statins and risk of hepatocellular carcinomaSystematic review with network meta-analysis: Comparative efficacy of oral nucleos(t)ide analogues for the prevention of chemotherapy-induced hepatitis B virus reactivation.Systematic Review with Network Meta-Analysis: Antidiabetic Medication and Risk of Hepatocellular Carcinoma.Increased levels of systolic blood pressure within the normal range are associated with significantly elevated risks of nonalcoholic fatty liver diseaseNonalcoholic fatty liver disease: a negative risk factor for colorectal cancer prognosis.Association between sex-specific serum uric acid and non-alcoholic fatty liver disease in Chinese adults: a large population-based study.Establishment and Validation of GV-SAPS II Scoring System for Non-Diabetic Critically Ill Patients.Metabolic syndrome contributes to an increased recurrence risk of non-metastatic colorectal cancer.Conditional survival estimate of acute-on-chronic hepatitis B liver failure: a dynamic prediction based on a multicenter cohortStratified neutrophil-to-lymphocyte ratio accurately predict mortality risk in hepatocellular carcinoma patients following curative liver resection.Increased levels of low-density lipoprotein cholesterol within the normal range as a risk factor for nonalcoholic fatty liver disease.Parabolic relationship between sex-specific serum high sensitive C reactive protein and non-alcoholic fatty liver disease in Chinese adults: a large population-based study.Preoperative platelet to lymphocyte ratio is a valuable prognostic biomarker in patients with colorectal cancer.Platelet-to-Lymphocyte Ratio: A Novel Prognostic Factor for Prediction of 90-day Outcomes in Critically Ill Patients With Diabetic Ketoacidosis.Targeting fibroblast growth factor 19 in liver disease: a potential biomarker and therapeutic target.Systematic review with network meta-analysis: adjuvant chemotherapy for resected colorectal liver metastases.Decellularization technology in CNS tissue repair.Recent advances in re-engineered liver: de-cellularization and re-cellularization techniques.Autophagy in ethanol-exposed liver disease.New advances in liver decellularization and recellularization: innovative and critical technologies.Serum uric acid: a new therapeutic target for nonalcoholic fatty liver disease.The role of lncRNAs in hepatocellular carcinoma: opportunities as novel targets for pharmacological intervention.Kidney bioengineering in regenerative medicine: An emerging therapy for kidney disease.Nucleos(t)ide analogues for preventing HBV reactivation in immunosuppressed patients with hematological malignancies: a network meta-analysis.Comparative efficacy of oral nucleotide analogues for the prophylaxis of hepatitis B virus recurrence after liver transplantation: a network meta-analysis.Combined AFP-CRUT with microvascular invasion accurately predicts mortality risk in patients with hepatocellular carcinoma following curative liver resection.Comparative efficacy and safety of immunosuppressive therapies for systemic sclerosis related interstitial lung disease: A Bayesian network analysisHNRNPAB-regulated lncRNA-ELF209 inhibits the malignancy of hepatocellular carcinoma
P50
Q26768128-2F0E4667-3369-4A15-B282-383BD684E490Q26824664-97F44B3C-C7DF-406F-9802-BED291D2CB78Q26864932-420B3BB7-DBE3-4996-AA6F-B1F7B17A8BC0Q28087211-D56C4C39-4B94-4AE2-A2C7-3825A0D21E3EQ35561845-28CC09C4-0F1E-4DBA-9F20-7C9B009ABC44Q35658230-520941C4-F647-4B49-A4EA-978D9AD3700FQ35660038-ED918727-36CB-44F8-BAE8-3830267FA236Q35778052-25990E4B-A201-4692-80D6-86D57FF3B22BQ35946029-7C4C5E1A-9FE3-433F-B96B-419E5BEE1FAFQ36001152-8DFE1470-867F-460B-A545-50CD2FEF5544Q36136847-0D7FFE6B-3C87-45D5-BE4A-4EC41BBE70D4Q36151646-556603CC-E1E1-4956-91E1-1016C5C8DFCFQ36152268-B9E4CBE8-5839-433E-855C-4705A035E56EQ36153675-E1405D12-6977-4C64-978C-3D5DCE811FC9Q36185812-E81D7268-7BE5-4563-BDF3-A860A3937E92Q36260667-E2000604-3EB7-4C8E-8D52-B3E042C75D03Q36414158-79BAF476-1A86-4B26-BD8A-A7914DEA44E8Q36905681-ACDB1C89-A54A-476B-B6D5-4CC9B8F85B42Q36905761-0A5614B8-ADF5-4AB3-B160-FD480450BCCCQ37046588-58F63FC9-D468-4DC7-8FAC-6CEDA80B4804Q37295401-CF4E880A-1819-46F5-84F2-BECC999990A5Q37624105-493961F1-FF16-419E-B86A-69BCC39DB800Q38303270-DAAE3875-E8A9-4407-A8F7-DFE572AF4782Q38311380-A997AC98-C4F2-434F-8D1C-5DF3FC8F67E4Q38393959-2265112B-1A08-4879-AF2B-E1AD910D25EAQ38485169-7A473C2B-30E4-43C7-B0E0-C1EB896988DCQ38549452-6157AC6E-3856-4D84-8ADB-2185EBE0355BQ38556438-4B0C3F7E-9E29-4BD3-AFC6-04BAEDEC4CCFQ38595252-5D194F3B-1675-489B-A5EE-20E7E74F9907Q38630563-2C3C3006-B9DD-4120-B33E-AE5F9541A53BQ38643943-3BDDC8AB-C63E-4D10-93E7-E1C0EB17F5EAQ40285910-CBD9B0A6-97D0-4516-B8C4-9C5F51E5CB7FQ40588229-4CF2ABD3-F2EC-4D07-B212-BB3450C9489BQ41102632-ACA3D810-3326-4D79-B0BE-6B5EBF7C0DD8Q91589416-8FA8CF3B-0E9F-45FE-AC82-9672651B4E3DQ92029091-7A63FAF6-6403-40F8-B2A0-CDF4FA79CC06
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Gui-qi Zhu
@ast
Gui-qi Zhu
@en
Gui-qi Zhu
@es
Gui-qi Zhu
@nl
Gui-qi Zhu
@sl
type
label
Gui-qi Zhu
@ast
Gui-qi Zhu
@en
Gui-qi Zhu
@es
Gui-qi Zhu
@nl
Gui-qi Zhu
@sl
prefLabel
Gui-qi Zhu
@ast
Gui-qi Zhu
@en
Gui-qi Zhu
@es
Gui-qi Zhu
@nl
Gui-qi Zhu
@sl
P1053
H-9265-2017
P106
P31
P3829
P496
0000-0001-5089-6923